by Oligonucleotide synthesis is a process of chemically synthesizing short sequences of nucleic acids, which are then used in numerous end-use applications like diagnostics, therapeutics and research. Oligonucleotides find applications in molecular diagnostics, therapeutics and many research applications. The growing demand for custom synthesized oligonucleotides in areas of gene knockdown, DNA/RNA fingerprinting, antisense therapy, primer design and probe discovery is a key driver of this market. Custom oligonucleotide synthesis allows researchers to design and build DNA or RNA molecules with exact control over sequence and chemistry. This empowers researchers to interrogate biology with precision at the level of single gene or transcript.
The global Oligonucleotide Synthesis Market is estimated to be valued at US$ 4565 Bn in 2024 and is expected to exhibit a CAGR of 13% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends
Advanced Technologies Propel Custom Oligo Synthesis: Technological advancements in oligonucleotide synthesis methods enable accurate, rapid and high-throughput custom oligonucleotide production. Automation and parallel synthesis techniques have significantly increased oligo yield and decreased production time from days to hours. Next generation technologies like Microfluidic oligo synthesis further offer cost-effective, high purity oligos. Transition to automated systems boosts custom oligo capabilities of even small labs.
Increasing R&D Investments in Gene Therapies: Rising R&D investments by biotech and pharmaceutical players in developing oligonucleotide-based therapeutics for genetic disorders is a major market driver. Oligonucleotides act as genetic switches to turn off genes responsible for disease conditions. Therapies in clinical trials involving antisense oligonucleotides, siRNA and aptamers focus on diseases like cancer, neurological disorders, infectious diseases and rare genetic conditions. This augurs well for oligonucleotide synthesis market.
Porter’s Analysis
Threat of new entrants: Low capital requirements and limited research resources make entry relatively easy. However, the market is dominated by few major players with strong brand identity and economies of scale.
Bargaining power of buyers: Buyers have moderate bargaining power due to availability of substitutes and standardized nature of products. However, niche technologies provide some product differentiation.
Bargaining power of suppliers: Suppliers of raw materials and key technologies have significant influence given rising input costs and dependence of manufacturers.
Threat of new substitutes: Threat is moderate as new advanced techniques and therapeutics emerge at constant pace replacing existing modalities.
Competitive rivalry: Intense competition exists between existing major players to gain higher market share through innovations, partnerships and geographical expansions.
Key Takeaways
The global Oligonucleotide Synthesis Market is expected to witness high growth.
Regional analysis: North America dominates the global market due to increasing penetration of personalized medicine and availability of advanced healthcare infrastructure. Asia Pacific is expected to exhibit fastest growth over forecast period led by expanding biopharmaceutical sector and growing R&D investments in countries like China and India.
Key players operating in the Oligonucleotide Synthesis Market are Forte Research Systems (India), ICON plc (Ireland), Merge healthcare incorporated (U.S.), Bio-Optronics (U.S.), DSG INC (U.S.), ArisGlobal (India), ERT Clinical Bioclinica (U.S.), Oracle Corporation (U.S.), Medidata Solutions (U.S.), DATATRAK International, Inc. (U.S.), and MedNet Solutions, Inc., (U.S.) among others. Key players are engaging in strategies like acquisitions, new product launches and geographic expansions to strengthen their market position.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
